Ketamine: A Promising Treatment for Severe Depression and Suicidal Ideation

by

Major depressive disorder and other kinds of depression continue to be an important worldwide concern as millions suffer from severe and incapacitating mental illnesses. Products finding their way onto the market today as antidepressants, which take several weeks to begin having an impact, are unbeneficial to all. This has encouraged the quest for newer, quicker-acting therapies. Originally derived from the coca plant, hallucinogens have been used, especially in recent years, as a novel approach to treating depression with high suicidal risk. That is why the multilateral unique properties of ketamine, including its rapid-acting and efficiency for patients who have not received results from other treatments, turn the substance into a highly prospective instrument in the sphere of mental health. This article provides information on how ketamine works in the management of severe depression, the use of ketamine, the advantages of using ketamine, and the limitations tied to its use.

The Mechanism of Ketamine in Treating Depression

It is important to point out that ketamine is different from the classic antidepressant drugs in its action. Most of the antidepressants are selective serotonin reuptake inhibitors, norepinephrine dopamine reuptake inhibitors, or both, but ketamine has the property of being an N-methyl-D-aspartate (NMDA) receptor antagonist. Regarding the molecular mechanism of action, ketamine raises the NMDA receptor, which plays a critical role in regulating the brain’s glutamate system that deals with neural messaging, flexibility, and adaptability. Underside, this modulation of the glutamate system results in the rapid formation of synaptic connections and therefore plays a role in the swift and durable antidepressant action of ketamine.

Ketamine also interacts with other neurotransmitter systems, including the GABA-ergic interneurons, dopamine, and opioid receptors, and hence has therapeutic benefits. These various mechanisms indicate that ketamine may act on many of the routes involved in depression, and so it may be useful for the treatment of non-responders to ordinary procedures.

Yearwise Publication Trend on “ketamine”

Find publication trends on relevant topics

Clinical Use of Ketamine for Depression

The use of ketamine has been researched across different contexts as a clinical intervention for depression, and all trials have shown the ability of ketamine to decrease depressive symptoms quickly. The drug can be given in sub-psychotic doses, and usually it is given either via IV or spoon administration. can experience vast improvements in mood several hours after the first dose of ketamine. Such a quick response is particularly important for people with treatment-refractory depression, in which conventional antidepressants do not work.

Ketamine has also been determined to have the effect of decreasing suicidal thoughts, which is an element of severe depression. Patients in the clinical trials using ketamine showed a significant decrease in suicidal ideation, with the results being evidenced by a few hours after administration of the drug. This quick action is important in emergency-related care because patients with acute suicidal preoccupation require quick attention to stop the suicide process.

Ketamine and Suicidal Ideation: A Lifesaving Tool

The other promising feature of ketamine treatment in mental health is that it extinguishes suicidal thoughts quickly. Far from providing immediate relief from suicidal thoughts, conventional therapies such as selective serotonin reuptake inhibitors (SSRIs) usually take weeks to work. Ketamine is, however, able to suppress these thoughts within hours, affording the patient some time for other effective solutions to settle in. hours,

The precise nature of ketamine’s positive impact on suicidal intent is not entirely understood, although it is thought that its effect on the glutamate system is key. Ketamine increases synaptic connections within a short time and thus improves communication between neurons, as well as reducing hopelessness and despair, which are the major drives towards suicidal thoughts.

Safety and Side Effects of Ketamine

However, it is not without its problems when applied to treating depression and suicidal thoughts in particular. Some of the challenges that might be of great concern include the possibility of abuse because the drug has been well-known to be a party drug. Still, when it comes to officially approved medications for the treatment of depression, the doses are an order of magnitude lower than the doses ordinarily employed in recreational use, and the risk of chemical dependence is kept to a minimum.

One issue in question is that ketamine may have certain side effects. Some of the common side effects are feelings of dissociation, the patient possibly feelingspaced out’ and not fully aware, dizziness, nausea, and an increase in blood pressure. These effects are normally considered to be short-term and are likely to wear off after some time as the drug takes effect, but some patients find these effects unpleasant.

Research about the safety of ketamine for long-term use for depression is still scarce, but from available data, it is evident that ketamine can be safely used if patients are regularly monitored and strict dose regimes are followed. In treating patients with ketamine, they are usually observed more closely when ketamine is being administered to them and during the time immediately after the administration of the drug to be able to prevent or deal with any side effects that might result from the drug.

Recent Publications on “ketamine”

Find publications on relevant topics

Ketamine from NOW to FUTURE: ADVANCES IN MENTAL HEALTH TREATMENT

Since ketamine was proven to be effective in the treatment of cases of severe depression and suicidal thoughts, there has been continued research into the use of ketamine and the creation of new substances based on it. Esketamine exists as a medicine and is the S-enantiomer of ketamine, also known as the party drug. It is used because of its effectiveness in the treatment of depression and is administered through nasal spray. It has already been approved by the FDA for the treatment of TRD (treatment-resistant disease). depression). This approval is a major step toward the general acceptance of ketamine as a standard therapy for diseases of the psyche.

Current research is trying to establish whether ketamine and its analogs would be effective for other disorders of thought, for example, anxiety disorders, PTSD, and bipolar disorder. These findings might further approve ketamine as a therapy for patients with treatment-refractory disorders in a mental health care setting.

Also, studies are underway in an attempt to increase the therapeutic effects of ketamine and reduce the side effects. Some of the strategies involve analyzing other routes of administration of ketamine, like oral or through the skin, and assessing the possibility of putting ketamine together with other treatment methods in a bid to enhance its safety and efficacy.

Conclusion

Ketamine is not just a new treatment for severe depression and suicidal thoughts; it has a positive effect on patients who have bad outcomes using standard medicines. Another peculiar feature of this medication and, at the same time, one of the main aspects rendering it very efficient in the treatment of mental disorders is its ability to influence suicidal thinking very quickly; the shifts may be observed even in the space of a couple of hours. There are always fears of risks and misuse, but in a strictly regulated clinical environment, ketamine has proven to be an effective and possibly life-saving tool. Given increasing knowledge about the specific ways ketamine can be utilized, it appears that the substance may become the primary foundation of treatment for major mental disorders for those who have failed all other therapies.

References

  1. Abbar, M., Demattei, C., El-Hage, W., Llorca, P.M., Samalin, L., Demaricourt, P., Gaillard, R., Courtet, P., Vaiva, G., Gorwood, P. and Fabbro, P., 2022. Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial. bmj, 376.
  2. Bonnet, U., 2015. Long-term ketamine self-injections in major depressive disorder: focus on tolerance in ketamine’s antidepressant response and the development of ketamine addiction. Journal of Psychoactive Drugs, 47(4), pp.276-285.
  3. Niesters, M., Martini, C. and Dahan, A., 2014. Ketamine for chronic pain: risks and benefits. British journal of clinical pharmacology, 77(2), pp.357-367.
  4. Zanos, P., Moaddel, R., Morris, P.J., Riggs, L.M., Highland, J.N., Georgiou, P., Pereira, E.F., Albuquerque, E.X., Thomas, C.J., Zarate, C.A. and Gould, T.D., 2018. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacological reviews, 70(3), pp.621-660.
  5. Morgan, M.M., Perina, D.G., Acquisto, N.M., Fallat, M.E., Gallagher, J.M., Brown, K.M., Ho, J., Burnett, A., Lairet, J., Rowe, D. and Gestring, M.L., 2021. Ketamine use in prehospital and hospital treatment of the acute trauma patient: a joint position statement. Prehospital Emergency Care, 25(4), pp.588-592.
  6. Wang, C., Zheng, D., Xu, J., Lam, W. and Yew, D.T., 2013. Brain damages in ketamine addicts as revealed by magnetic resonance imaging. Frontiers in neuroanatomy, 7, p.54549.
  7. Hong, Y.L., Yee, C.H., Tam, Y.H., Wong, J.H., Lai, P.T. and Ng, C.F., 2018. Management of complications of ketamine abuse: 10 years’ experience in Hong Kong. Hong Kong Medical Journal, 24(2), p.175.

Top Experts on “ketamine“